Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs

T. Lopotová, J. Polák, J. Schwarz, H. Klamová, J. Moravcová

. 2012 ; 49 (1) : 41-47.

Language English Country United States

Document type Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT12392 MZ0 CEP Register

Although the mechanism of action of leukemic oncogene Wilms' tumor gene 1 (WT1) remains unclear, WT1 has already been used in monitoring of patients with acute myeloid leukemia (AML) and it is being tested for immunotherapy. More detailed understanding of the role of WT1 in leukemia may improve its utilization. At least 36 isoforms may be produced. Four major variants denoted as -5/-KTS, -5/+KTS, +5/-KTS and +5/+KTS are produced by combining splicing of exon 5 and KTS sequence. In this study, we report applicability of newly developed real-time RT PCRs enabling for the first time full quantification of the four major WT1 splicing variants. Following careful optimization and testing of quantification reliability of four assays, we analyzed 34 samples of patients with AML and 12 samples of patients with chronic myeloid leukemia (CML) at the time of diagnosis. Analyses of five more CML patients provided insight into WT1 variants expression kinetics. We found predominance of +5/+KTS in both diagnoses. Comparison of WT1 variant expression in AML and CML patients' groups differing in response to therapy suggested possible importance of particular WT1 variant levels as markers of further disease course.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12034529
003      
CZ-PrNML
005      
20170502144509.0
007      
ta
008      
121023s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bcmd.2012.04.001 $2 doi
035    __
$a (PubMed)22555024
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lopotová, Tereza $u Institute of Hematology and Blood Transfusion, Department of Cellular Biochemistry, U Nemocnice 1, 128 20, Prague 2, Czech Republic. Tereza.Lopotova@uhkt.cz $7 xx0128722
245    10
$a Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs / $c T. Lopotová, J. Polák, J. Schwarz, H. Klamová, J. Moravcová
520    9_
$a Although the mechanism of action of leukemic oncogene Wilms' tumor gene 1 (WT1) remains unclear, WT1 has already been used in monitoring of patients with acute myeloid leukemia (AML) and it is being tested for immunotherapy. More detailed understanding of the role of WT1 in leukemia may improve its utilization. At least 36 isoforms may be produced. Four major variants denoted as -5/-KTS, -5/+KTS, +5/-KTS and +5/+KTS are produced by combining splicing of exon 5 and KTS sequence. In this study, we report applicability of newly developed real-time RT PCRs enabling for the first time full quantification of the four major WT1 splicing variants. Following careful optimization and testing of quantification reliability of four assays, we analyzed 34 samples of patients with AML and 12 samples of patients with chronic myeloid leukemia (CML) at the time of diagnosis. Analyses of five more CML patients provided insight into WT1 variants expression kinetics. We found predominance of +5/+KTS in both diagnoses. Comparison of WT1 variant expression in AML and CML patients' groups differing in response to therapy suggested possible importance of particular WT1 variant levels as markers of further disease course.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a alternativní sestřih $7 D017398
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a buňky K562 $7 D020014
650    _2
$a chronická myeloidní leukemie $x diagnóza $x metabolismus $x terapie $7 D015464
650    _2
$a akutní myeloidní leukemie $x diagnóza $x metabolismus $x terapie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a proteiny WT1 $x biosyntéza $7 D025721
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Polák, Jaroslav $7 xx0070555 $u Charles University, Albertov 6, 128 43, Prague 2, Czech Republic
700    1_
$a Schwarz, Jiří, $d 1957- $7 xx0052837 $u Institute of Hematology and Blood Transfusion, Clinical Department, U Nemocnice 1, 128 20, Prague 2, Czech Republic
700    1_
$a Klamová, Hana $7 xx0081721 $u Institute of Hematology and Blood Transfusion, Clinical Department, U Nemocnice 1, 128 20, Prague 2, Czech Republic
700    1_
$a Moravcová, Jana $7 xx0053080 $u Institute of Hematology and Blood Transfusion, Department of Cellular Biochemistry, U Nemocnice 1, 128 20, Prague 2, Czech Republic
773    0_
$w MED00005053 $t Blood cells, molecules & diseases $x 1096-0961 $g Roč. 49, č. 1 (2012), s. 41-47
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22555024 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20121023 $b ABA008
991    __
$a 20170502144836 $b ABA008
999    __
$a ok $b bmc $g 956539 $s 792026
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 49 $c 1 $d 41-47 $i 1096-0961 $m Blood cells, molecules, & diseases $n Blood Cells Mol Dis $x MED00005053
GRA    __
$a NT12392 $p MZ0
LZP    __
$b NLK112 $a Pubmed-20121023

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...